Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA gene therapy office director

Executive Summary

Center for Biologics Evaluation & Research's Office of Cellular, Tissue & Gene Therapies' new director is Celia Witten. She was previously head of the Center for Devices & Radiological Health's Division of General, Restorative & Neurological Devices. The gene therapy office had been headed by former Intronn COO Edward Otto, who joined in November (1"The Pink Sheet" Nov. 1, 2004, In Brief). Otto left "to pursue outside interests," the agency said. Witten assumed her new role March 7...

Center for Biologics Evaluation & Research's Office of Cellular, Tissue & Gene Therapies' new director is Celia Witten. She was previously head of the Center for Devices & Radiological Health's Division of General, Restorative & Neurological Devices. The gene therapy office had been headed by former Intronn COO Edward Otto, who joined in November (1 'The Pink Sheet' Nov. 1, 2004, In Brief). Otto left "to pursue outside interests," the agency said. Witten assumed her new role March 7....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel